Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119162782 | 11916278 | 2 | F | 20010417 | 20160825 | 20160114 | 20160825 | EXP | DE-BRISTOL-MYERS SQUIBB COMPANY-11545233 | BRISTOL MYERS SQUIBB | 0.00 | DY | F | Y | 1.24000 | KG | 20160825 | OT | US | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119162782 | 11916278 | 1 | PS | STAVUDINE. | STAVUDINE | 1 | Transplacental | 80 MG, QD | U | 20412 | 80 | MG | QD | ||||||
| 119162782 | 11916278 | 2 | SS | VIRAMUNE | NEVIRAPINE | 1 | Transplacental | 400 MG, QD | U | 0 | 400 | MG | QD | ||||||
| 119162782 | 11916278 | 3 | SS | EPIVIR | LAMIVUDINE | 1 | Transplacental | 150 MG, QD | U | 0 | 150 | MG | QD | ||||||
| 119162782 | 11916278 | 4 | SS | COMBIVIR | LAMIVUDINEIDOVUDINE | 1 | Transplacental | 900 MG, QD | U | 0 | 900 | MG | QD | ||||||
| 119162782 | 11916278 | 5 | SS | NORVIR | RITONAVIR | 1 | Transplacental | 200 MG, QD | 6400 | MG | U | 0 | 200 | MG | QD | ||||
| 119162782 | 11916278 | 6 | SS | FORTOVASE | SAQUINAVIR | 1 | Transplacental | 2000 MG, QD | 64000 | MG | U | 0 | 2000 | MG | QD | ||||
| 119162782 | 11916278 | 7 | SS | RETROVIR | ZIDOVUDINE | 1 | Transplacental | 100 MG, QD | U | 0 | 100 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119162782 | 11916278 | 1 | Product used for unknown indication |
| 119162782 | 11916278 | 2 | Product used for unknown indication |
| 119162782 | 11916278 | 3 | Product used for unknown indication |
| 119162782 | 11916278 | 4 | Product used for unknown indication |
| 119162782 | 11916278 | 5 | Product used for unknown indication |
| 119162782 | 11916278 | 6 | Product used for unknown indication |
| 119162782 | 11916278 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119162782 | 11916278 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119162782 | 11916278 | Anaemia | |
| 119162782 | 11916278 | Erythroblastosis | |
| 119162782 | 11916278 | Foetal exposure during pregnancy | |
| 119162782 | 11916278 | Hyperbilirubinaemia | |
| 119162782 | 11916278 | Hypotension | |
| 119162782 | 11916278 | Premature baby |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119162782 | 11916278 | 1 | 200010 | 0 | ||
| 119162782 | 11916278 | 2 | 200010 | 0 | ||
| 119162782 | 11916278 | 3 | 200010 | 0 | ||
| 119162782 | 11916278 | 4 | 20010416 | 0 | ||
| 119162782 | 11916278 | 5 | 20010316 | 20010416 | 0 | |
| 119162782 | 11916278 | 6 | 20010316 | 20010416 | 0 | |
| 119162782 | 11916278 | 7 | 20010417 | 20010417 | 0 |